Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
Atomoxetine Aurobindo 40 mg hard capsules, Microcrystalline cellulose gelatin capsule
Disc Medicine
Parkinson's disease
1 trial -
Atorvastatin
Regeneron UK Limited
Hypercholesterolemia
1 trial -
Attentin 10 mg Tablette, Dexamfetamine sulfate 20 mg modified-release capsule, Placebo for Test 1 - 5 mg, Attentin 5 mg, Tablette, Placebo for test 2 - 10 mg, Placebo for test 1 - 10 mg, Placebo for test 2 - 20 mg, Dexamfetamine sulfate 15 mg modified-release capsule, Placebo for test 2 - 15 mg, Dexamfetamine sulfate 10 mg modified-release capsule
Medice Arzneimittel PΓΌtter GmbH & Co. KG
Patients with ADHD (according to ICD-10 / DSM-5)
1 trial -
Atumelnant 120 mg tablets, Atumelnant 80 mg tablets, Tablet
Lacuna Pharma Pty Ltd
Classic Congenital Adrenal Hyperplasia
1 trial -
Atumelnant 80 mg tablets, Atumelnant 40 mg tablet, Atumelnant 20 mg tablets, Tablet
Lacuna Pharma Pty Ltd
Classic congenital adrenal hyperplasia
1 trial -
Avastin 25 mg/ml concentrate for solution for infusion., Lonsurf 20 mg/8.19 mg film-coated tablets, Lonsurf 15 mg/6.14 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Avastin 25 mg/ml concentrate for solution for infusion.
The George Institute
Metastatic colorectal cancer
1 trial -
Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM LEVOFOLINATE , MK-1084, CETUXIMAB , MVASI 25 mg/mL concentrate for solution for infusion, FLUOROURACIL , Avastin 25 mg/ml concentrate for solution for infusion., MK-1084, CALCIUM FOLINATE , OXALIPLATIN , MK-1084, MVASI 25 mg/mL concentrate for solution for infusion
Merck Sharp and Dohme
KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer
1 trial -
Azacitidine Combined With Venetoclax and ATRA group
The First People's Hospital of Lianyungang
Acute Myeloid Leukemia
1 trial -
Azacitidine, Cedazuridine, Azacitidine, Vidaza 25 mg/ml powder for suspension for injection, Azacitidine, Cedazuridine
Taiho Pharma Netherlands B.V.
Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML)
1 trial -
Azathioprine
The First People's Hospital of Lianyungang
Myasthenia Gravis
1 trial -
Azelastine hydrochloride and Fluticasone propionate
Teva Pharma GmbH
Seasonal Allergic Rhinitis
1 trial -
B/F/TAF
Gilead Sciences Ireland UC
HIV-1/HBV Co-Infection
1 trial -
B/F/TAF (Adult Strength)
Gilead Sciences Ireland UC
HIV-1 Infection
1 trial -
B013+Nab-Paclitaxel
BRIGHT MINDS BIOSCIENCES INC.
Triple Negative Breast Cancer (TNBC)
1 trial -
BAF312, FINGOLIMOD HYDROCHLORIDE, BAF312, BAF312, Placebo to Ofatumumab (OMB157) [Kesimpta], BAF312, OFATUMUMAB, BAF312, Placebo to Siponimod (BAF312) [Mayzent] film-coated tablets, Placebo to Fingolimod (FTY720) [Gilenya] 0.25mg & 0.5mg, FINGOLIMOD HYDROCHLORIDE
Novartis Pharmaceuticals
Multiple Sclerosis in pediatric patients
1 trial -
BARICITINIB, Baricitinib, BARICITINIB, BARICITINIB
Eli Lilly Co.
Juvenile Idiopathic Arthritis
1 trial -
BARICITINIB, TRIAMCINOLONE ACETONIDE, BARICITINIB, HYDROCORTISONE, Baricitinib, Placebo to match 4 mg tablet, BARICITINIB, HYDROCORTISONE, Hydrocutan Creme 1 %, Placebo to match 2mg tablet, Placebo to match 1mg tablet, Placebo to match 2mg/ml oral suspension
Eli Lilly Co.
Atopic Dermatitis
1 trial -
BAY 1841788, NUBEQA 300 mg film-coated tablets, Saruparib, ZYTIGA 250 mg tablets, Xtandi - 40 mg film-coated tablets, ZYTIGA 500 mg film-coated tablets, Placebo to match (PTM) tablets, Abiraterone Teva 500 mg film-coated tablets
AstraZeneca AB
Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
1 trial -
BAY 1841788, TRIPTORELIN
Ningbo Cancer Hospital
Patients with localised prostate cancer and high-risk features of relapse (minimum 2 high-risk criteria from National Comprehensive Cancer Network (NCCN) classification)1 and with no detectable metastasis, including no evidence of pelvic lymph node metastasis on next-generation imaging (PSMA PET/CT).
1 trial -
BAY 3427080, BAY 3427080 60 mg capsules placebo
Bayer AG
Vasomotor symptoms caused by adjuvant endocrine therapy in women with, or at high risk for developing hormone-receptor positive breast cancer
1 trial -
BAY 94-8862, Finerenone, Placebo coated tablet 002 to BAY 948862 coated tablet
The George Institute
Chronic kidney disease
1 trial -
BAY 94-8862, Placebo to Finerenone 10 film-coated tablets, Placebo to BAY 948862, BAY 948862, Placebo to Finerenone 20 film-coated tablets, Finerenone
Bayer AG
Proteinuria, Chronic kidney disease
1 trial -
BCG VACCINE , JNJ-63723283, JNJ-17000139, JNJ-63723283
Janssen-Cilag International N.V.
High-Risk Non-muscle-invasive Bladder Cancer
1 trial -
BCX7353 capsules
Biocryst
Hereditary Angioedema
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources